Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Agronomics Limited (AGNMF)
Ramsey, IM
Agronomics Limited operates as a principal investment firm, deploying capital across various financial instruments, including funds, equity, and equity-linked products. Its portfolio encompasses both publicly traded and privately held companies. A primary emphasis is placed on pioneering sectors such as alternative proteins, particularly those involved in cellular agriculture and other emerging modern food technologies. The firm is also deeply committed to the biopharma sector, actively constructing a robust portfolio of investments in both biotechnology and pharmaceutical enterprises. Beyond direct equity, Agronomics may allocate capital to collective investment schemes concentrated on the biopharma industry, as well as long-term equity anticipation securities (LEAPS) whose underlying assets are biopharma-related stocks or indices. Additionally, the firm retains the option to invest in biopharma sector debt, though such exposures are capped at 15 percent of the company's net asset value. Established on May 3, 2011, Agronomics Limited is headquartered in Ramsey, Isle of Man.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.35% | -10.50% | -6.77% | -18.64% | -0.56% | +6.93% | -0.22% | -28.40% | -74.57% | +54.84% | +54.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Asset Management: +17.4%+96.1% ★ Q4'25: -100.0% (vs Q4'23)
-
EPS growth Asset Management: +22.7%-304.6% Q4'25: +2,575.0% (vs Q4'23)
-
FCF margin FCF growth · Asset Management: +27.7%+222.3%
-
EBIT margin Asset Management: +50.6%+222.2% ★
-
ROIC Asset Management: +6.5%— Q4'25: -29,769.8% (vs Q4'23)
-
Share dilution Asset Management: +0.0%+38.6% Q4'25: +37.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Asset Management: -0.03×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2026 1 Rev. Ana. |
Jun 2027 1 Rev. Ana. |
Jun 2028 1 Rev. Ana. |
Jun 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.28M
est: 737.7K (+73.2%)
|
10.67M
est: 7.41M (+44.1%)
|
440.3K
est: 20.05M (-97.8%)
|
29.70M
est: 24.59M (+20.8%)
|
737.7K
737.7K – 737.7K
-97.0% YoY
|
7.41M
7.41M – 7.41M
+904.0% YoY
|
20.05M
20.05M – 20.05M
+170.7% YoY
|
24.59M
24.59M – 24.59M
+22.7% YoY
|
| EBITDA |
—
est: 269.5K (-100.0%)
|
—
est: 2.71M (-100.0%)
|
1.50M
est: 7.33M (-79.5%)
|
24.56M
est: 8.99M (+173.4%)
|
417.1K
417.1K – 417.1K
-95.4% YoY
|
4.19M
4.19M – 4.19M
+904.0% YoY
|
11.34M
11.34M – 11.34M
+170.7% YoY
|
13.90M
13.90M – 13.90M
+22.7% YoY
|
| EBIT |
555.8K
est: 515.3K (+7.9%)
|
2.46M
est: 5.17M (-52.5%)
|
22.5K
est: 14.01M (-99.8%)
|
24.56M
est: 17.18M (+43.0%)
|
598.6K
598.6K – 598.6K
-96.5% YoY
|
6.01M
6.01M – 6.01M
+904.0% YoY
|
16.27M
16.27M – 16.27M
+170.7% YoY
|
19.96M
19.96M – 19.96M
+22.7% YoY
|
| Net Income |
611.7K
est: -990.8K (+161.7%)
|
1.02M
est: 11.00M (-90.7%)
|
8.36M
est: 13.03M (-35.8%)
|
22.37M
est: 18.33M (+22.1%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| SGA |
615.7K
est: 2.14M (-71.2%)
|
7.42M
est: 21.46M (-65.4%)
|
5.82M
est: 58.09M (-90.0%)
|
4.13M
est: 71.25M (-94.2%)
|
2.07M
2.07M – 2.07M
-97.1% YoY
|
20.74M
20.74M – 20.74M
+904.0% YoY
|
56.16M
56.16M – 56.16M
+170.7% YoY
|
68.88M
68.88M – 68.88M
+22.7% YoY
|
| EPS |
0.01
est: 0.00 (+765.8%)
|
0.00
est: 0.01 (-80.0%)
|
0.01
est: 0.01 (-27.1%)
|
0.02
est: 0.02 (+23.8%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Mellon | Co-Founder & Executive Chairperson | 53.7K | male |
| Denham Hervey Newall Eke | Finance Director & Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AGNMF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
